Login to Your Account

Phase II Data Keep AM-101 on Track for Pivotal Trials

By Cormac Sheridan
Staff Writer

Monday, September 9, 2013
With the start of a Phase III trial of its lead compound tinnitus drug AM-101 imminent, Auris Medical AG has completed a second Phase II trial, which further rounds out its understanding of how to administer the therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription